Articles tagged with Tumor Growth
Researchers found that leftover cancer cell debris can stimulate tumor growth, but resolvins can block this response. The study suggests a new approach to enhance cancer therapy and prevent recurrence.
Researchers discovered that chemotherapy can stimulate tumor growth by inducing an inflammatory reaction in the body. Resolvins, a family of molecules, have been found to suppress this response, suggesting new ways to enhance cancer therapy effectiveness.
Research reveals that bone marrow-derived cells contribute to lung cancer progression by stimulating the production of specific neutrophils. These neutrophils exhibit increased expression of genes associated with tumor-promoting processes, leading to worse patient survival in a small study.
Researchers at Beth Israel Deaconess Medical Center have shown that chemotherapy-generated debris can stimulate tumor growth, but resolvins can suppress this effect. The findings offer a novel treatment approach to prevent cancer recurrence.
Researchers at NIST developed a novel method for measuring tumor growth using disposable diapers as 'phantoms' with water. Volumetric measurement proved more accurate than the traditional RECIST approach, potentially enabling earlier and more effective cancer screenings.
Researchers at RUDN University have synthesized new compounds with potential antitumor and antiviral activity from isoxazoles. The compounds, which include a central five-membered heterocycle, exhibit varying properties depending on the arrangement of substituents.
A study published in Cancer Research found that inhibiting two metabolic enzymes, NADK and KHK, reduced the growth of KRAS-mutant colorectal cancer cells in mice by approximately 50%. The research also identified new genes that, when inactivated, increased tumor growth in KRAS-mutant cancers.
Researchers at the University of Southern Denmark have discovered a new strategy to overcome resistance in lung cancer, which often leads to treatment failure. By combining an EGFR tyrosine kinase inhibitor with an AKT inhibitor, tumor growth can be arrested, potentially improving patient survival.
Epithelial tumours can grow independently of their microenvironment, driven by a feedback amplification loop that activates the JNK stress signalling pathway. This internal mechanism triggers proliferation in non-proliferating cells, leading to chromosomal instability and loss of epithelial polarity.
Researchers have found that the Tie2 receptor on pericytes plays a crucial role in regulating blood vessel growth and maturation. By breeding mice with disabled Tie2 receptors, scientists discovered that tumor blood vessels grew faster and more aggressively without this control, highlighting potential new targets for cancer therapy.
Researchers have identified a crucial pathway in regulating cellular metabolism, which they believe could be targeted to control tumor growth. The study found that blocking this pathway reduced tumor growth in melanoma mice and holds promise for developing new cancer treatments.
Researchers found that PTEN, a frequently deleted tumor suppressor gene in cancer, can regulate oncogene expression by increasing the deposition of DAXX and H3.3 onto chromatin. The study showed that eliminating both genes led to a synthetic growth defect, slowing down tumor growth.
A Georgia State University researcher is studying how to reduce tumor growth in lung cancer using a $2.3 million grant. The goal is to identify novel targets for treatment, as tumors become resistant to current therapies and promote new blood vessel formation.
Combining anti-angiogenic and immune-stimulating therapies creates specialized blood vessels that deliver cancer-fighting immune cells to tumors, leading to better therapeutic outcomes. This breakthrough research may improve treatments and prolong survival periods for patients.
A study published in JAMA Dermatology found that actinic keratosis management costs differ significantly across regions. The researchers discovered that understanding these geographic variations can help identify areas with excessive spending and potential for cost savings.
Researchers at Northwestern University have found a molecule that stops the growth of diffuse intrinsic pontine glioma (DIPG), a fatal pediatric brain tumor. The study, published in Nature Medicine, reveals the molecule detaches proteins that enable cancer cells to grow, offering new treatment options for children under 10.
Researchers at McGill University have discovered that targeting the biological clock in cancer cells can inhibit tumor growth. By 'repairing' the malfunctioning clock, tumors grew nearly half as fast as those without such intervention, suggesting a potential new way to treat cancer in humans.
Researchers identified a critical phosphorylation process in PHD2 that slows down cancer growth. Blocking the enzyme PP2A/B55 restores PHD2 function, suggesting a promising new approach for targeted cancer therapy.
A new UCL study reveals that tumor growth exerts mechanical forces on blood vessels, compressing or collapsing them to block oxygen delivery. This can lead to uneven drug delivery and reduced treatment effectiveness.
Researchers found a way to inhibit glioblastoma growth by targeting neurodevelopmental transcription factors, which drive brain tumor growth. A chemotherapy drug called mithramycin can prevent further tumor growth with minimal side effects.
Scientists at Indiana University have discovered that fruit flies produce a molecule similar to cancer-causing compounds, offering a new model for studying this molecule. The study reveals the molecular mechanism behind the production of L-2HG in healthy and diseased cells.
Researchers have discovered a potential new approach to treating triple negative breast cancer by targeting enhanced mitochondrial function. Mice studies showed that inhibiting mitochondrial protein translation could slow tumor growth, suggesting this strategy may be a successful treatment option.
The study found that KLF12 promotes colorectal cancer (CRC) cell growth by activating early growth response protein 1 (EGR1), leading to enhanced cancer cell proliferation and survival. KLF12 and EGR1 levels synergistically correlate with poor CRC prognoses, suggesting their potential as novel therapeutic targets.
Researchers found that celecoxib, a widely prescribed pain and anti-inflammatory drug, slows the growth rate of neurofibromatosis type II (NF2) tumors in animal models. The study suggests that COX-2 inhibitors may have an impact on tumor formation and inflammatory responses.
A team of researchers from the University of Hong Kong has successfully developed a novel strategy for synthesizing cortistatin A, a molecule with potent anti-angiogenic activity. This breakthrough could lead to the creation of more effective anti-cancer therapies.
Researchers discovered that breast cancer cells require fatty acids from the extracellular environment to proliferate. LIPG enzyme is crucial for tumor growth, and its inhibition may lead to more efficient chemotherapy treatments.
Researchers at Scripps Florida aim to block breast cancer growth by targeting a specific microRNA that adapts cancer cells to low oxygen environments. Inhibiting this microRNA increases the sensitivity of cancer cells to death and makes them more vulnerable to chemotherapy.
Eliminating cancer-associated fibroblasts (CAFs) did not slow or halt tumor growth; in fact, it increased the risk of metastasis when done too late. CAFs play a complex role in cancer growth and metastasis.
A study examines the safety of propranolol therapy in infants with vascular tumors, finding severe respiratory and cardiac disorders are rare but significant. The treatment has been shown to induce regression, but caution is advised due to potential risks.
Mathematicians at Duke University develop a method to compare common tumor growth models using only two time-point measurements of tumor size. The results suggest breast and liver tumors grow exponentially, while neurological tumors follow the two-thirds power law.
Researchers discovered that lung cancer cells switch to using amino acid glutamine when glucose is scarce, allowing them to continue growing under starvation conditions. Blocking this enzyme PEPCK could slow tumor growth in mice, suggesting a promising new approach to treating non-small cell lung cancer.
A study led by University of Texas M. D. Anderson Cancer Center researchers identified EphB4 as a trigger for tumor growth via STAT3 protein regulation, linking cancer anemia treatment to tumor progression.
Researchers at IRB Barcelona have revived an old tissue transplant technique from 1935 to aid tumour growth studies in Drosophila melanogaster. The approach has been successfully reproduced and implemented by labs worldwide.
Researchers discovered a mechanism that regulates blood vessel growth in diabetic mice, reducing tumor size without harming other organs. The approach may also treat diabetic complications like retinopathy and nephropathy.
Researchers at IRB Barcelona found that tumor suppressor genes restrict the growth of neighboring cell populations, a mechanism that may contribute to cancer development. This discovery could provide insight into the early events of tumorigenesis and the selection of tumour-initiating cells.
Breast cancer researchers have gained new insights into the phases of tumor growth by visualizing and quantifying tumor development in real-time. The study reveals that tumors undergo a dramatic increase in cell number after four weeks, providing valuable information for treatment selection and delivery.
Researchers found that dasatinib inhibits proteins promoting cancer growth but also suppresses those protecting against it. The study suggests pretesting patient biopsies can help identify patients who may respond to dasatinib and those who should avoid it.
Researchers at the University of Copenhagen discovered a mechanism that controls ADAM17, an enzyme crucial for cancer tumour growth. By inhibiting PACS-2, they found a way to target ADAM17 without affecting other enzymes, potentially leading to improved cancer treatments.
A study by Singapore researchers established that gene p73 has both promotional and suppressive functions in tumor growth. The findings suggest that p73 is stabilized and activated under hypoxic conditions, promoting efficient blood vessel formation that supports tumor development.
A study published in the Journal of Leukocyte Biology suggests that pre-existing inflammation can promote the spread of cancer by raising levels of chitinase-3-like-1, a known biomarker of cancer. This increase in CHI3L1 leads to faster cancer growth and increased metastasis.
A new Stanford University School of Medicine study has found that brain tumor growth is stimulated by nerve activity in the cerebral cortex. The research, conducted in mice with human brain cancer implants, identified a specific protein called neuroligin-3 as responsible for the increase in tumor growth associated with neuronal activity.
Research shows exercise slows tumor growth and improves blood vessel perfusion, leading to reduced hypoxia and better response to chemotherapy. Exercise combined with chemotherapy results in slower tumor growth compared to sedentary mice or those treated with the drug alone.
A recent study has explored the effect of mutations in PKC on tumour growth, revealing that most 'loss of function' mutations stop PKC from working. The study found that correcting these mutations in bowel cancer cells resulted in a reduction in tumour growth.
Researchers at Indiana University School of Medicine identified a novel pathway that enables solid tumor cancer cells to grow. The protein Mdm2 plays an active role in making p53 ineffective, providing a new target for therapeutic approaches.
Scientists from the University of Manchester discovered that ATF2 protein suppresses tumour growth in liver cancer models. The study suggests that ATF2's tumor-suppressing function may be more widespread than previously thought.
Researchers discover PHD3 controls EGFR uptake, leading to uncontrolled cell growth and tumor proliferation. PHD3 loss is crucial for human malignant brain tumour growth under hypoxia.
Researchers inhibit autotaxin, an enzyme that promotes cancer cell survival and metastasis, decreasing tumor growth by up to 70% and improving chemotherapy effectiveness. The discovery offers a new therapy potential for breast and thyroid cancer patients.
Researchers at UC Davis found that diets rich in whole walnuts or walnut oil slowed prostate cancer growth in mice. The walnut diet also reduced levels of the hormone IGF-1, which had been previously implicated in both prostate and breast cancer.
Researchers have developed a synthetic anti-cancer molecule JK-31 that blocks the signalling of a 'growth factor' chemical promoting blood vessel networks to feed tumours. The molecule also inhibits a protein controlling cancer cell division and proliferation.
Researchers have discovered a new target for treating kidney cancer by targeting the Transient Receptor Potential Melastatin 3 channel. This channel promotes tumor growth and stimulates autophagy in cancer cells.
Researchers have discovered a new drug combination that disrupts two key signaling pathways that drive breast cancer growth, showing promise in treating the disease. The combination of rapamycin and dasatinib was found to be more effective than using either drug alone in killing tumors.
A new study found that high levels of miRNA-378a-5p cause cell division anomalies in breast cancer cells, leading to abnormal chromosome numbers and promoting cancer growth. Elevated levels of this microRNA also correlate with aggressive forms of breast cancer.
A new computational model developed at Princeton University may help understand tumor dormancy, a phenomenon that can last up to 25 years in pancreatic cancer. The model predicts that tumors are likely to grow rapidly when the number of dividing cells reaches a certain critical level.
A study published in the Journal of Clinical Endocrinology & Metabolism found that mutations in the ARMC5 gene promote the growth of benign tumors in the adrenal glands and meninges. This discovery provides new insights into the causes of Cushing's syndrome, a disease characterized by elevated cortisol levels.
Researchers identified a tumor vessel-specific protein, L1, as a potential therapeutic target to reduce tumor growth and metastasis. Loss of L1 in mouse pancreatic cancer models reduced tumor angiogenesis and promoted vessel normalization.
Scientists at Scripps Research Institute have successfully disrupted MYC, a cancer regulator thought to be undruggable, using a credit card-like molecule called KJ-Pyr-9. This breakthrough discovery shows the drug candidate can stop tumor growth in animal models and may offer new hope for cancer treatment.
Researchers at Dana-Farber Cancer Institute found that subgroups within tumors drive growth, rather than the fastest-proliferating cells. Targeting these growth-driving cells could improve treatment outcomes and prevent tumor expansion.
Scientists at UEA discover the cannabis compound THC can reduce tumor growth by targeting two specific cell receptors. The findings could lead to the development of a synthetic equivalent with anti-cancer properties.
Researchers have created a combination drug that controls both tumor growth and metastasis by combining a COX-2 inhibitor and an epoxide hydrolase (sEH) inhibitor. The study found that the dual inhibitor blocked angiogenesis, limiting tumor growth and metastasis in human lung and breast tumors.
A team of scientists found that losing p62 in surrounding cells enhances tumor growth and progression. The study suggests therapies targeting the tumor microenvironment may be as important as targeting the tumor itself.